Medical Research

Health·Medical Research·NASDAQ:JRNY·News·Pharmaceuticals

Journey Medical Shares Drop—DERM’s 2026 Outlook Hinges on Emrosi Trial

Journey Medical Corp shares fell 3.5% to $6.09 late Monday, trailing the SPDR S&P Biotech ETF’s 2.2% drop. The company last reported Q1 revenue up 21% to $16 million, with $6.3 million from rosacea drug Emrosi. Cash stood at $27.2 million as of March 31. The next investor event is the annual meeting on June 24.

June 2, 2026

ASX Stocks Positioned to Endure Market and Economic Changes
June 1, 2026, 8:15 PM EDT. This article discusses Australian Securities Exchange (ASX) stocks with strong potential to withstand decades of market volatility and economic shifts. It highlights the importance of companies with solid fundamentals and resilient business models that can adapt to changing conditions. The piece cautions that the content is for informational purposes only and does not serve as investment advice. Investors are urged to conduct their own research and seek guidance from qualified financial professionals. Emphasizing prudence, the article notes that past performance is not indicative of future results and advises consultation with advisers on tax, legal, and financial matters.